Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Feb 28, 2025

Keywords

ClinConnect Summary

This clinical trial is looking into a new way to give a treatment called 177Lu-PSMA-617 to patients with prostate cancer using a special device called a Totally Implantable Venous Access Port (TIVAP). Many patients who receive this treatment are older and may have difficulty using their veins for injections due to previous chemotherapy. Since many already have a TIVAP in place, this study is exploring whether it can be a good option for administering this therapy safely and effectively.

To participate in this trial, patients need to be men who are receiving Pluvicto as part of their prostate cancer treatment and have had a specific type of scan (SPECT/CT) shortly after their Pluvicto injection. Participants will help researchers understand how the treatment behaves when given through the TIVAP. It’s important for potential participants to know that their data will be used for research, so they will need to agree to that. Right now, the trial is not yet recruiting participants, but it aims to provide valuable information that could improve treatment options for prostate cancer patients in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with an injection of Pluvicto as part of the treatment of their prostate cancer, having had a SPECT/CT scan for dosimetry within 2 to 4 hours after injection.
• Exclusion Criteria:
• • Patients who have refused to have their data used for research purposes